Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Nov 9, 2023

Keywords

ClinConnect Summary

This clinical trial is looking into a new approach for treating inflammatory breast cancer, a rare and aggressive form of breast cancer. The goal is to see if patients who respond well to initial chemotherapy can safely undergo breast-conserving surgery instead of a more extensive surgery. Traditionally, patients with inflammatory breast cancer often need to have their entire breast removed, but recent advances in treatment may allow for a less invasive option if the cancer shows significant improvement after chemotherapy.

To participate in this trial, women aged 18 and older with inflammatory breast cancer that has responded completely to chemotherapy might be eligible. They must not have any spread of the cancer to other parts of the body and should not have any other serious health issues that would prevent them from receiving further treatment. If they join the trial, participants can expect close monitoring and care as they explore this promising approach to surgery. It's important to note that this trial is not yet recruiting participants, so those interested will need to wait for it to start.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with inflammatory breast cancer
• • Clinical complete response after neoadjuvant chemiotherapy
• • Targeted tumor
• • Written informed consent
• Exclusion Criteria:
• • Metastasis
• • Progression disease
• • Recurrent disease
• • Contraindications to adjuvant radiation therapy